Beyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F25%3A43928298" target="_blank" >RIV/00216208:11120/25:43928298 - isvavai.cz</a>
Výsledek na webu
<a href="https://doi.org/10.3390/ph18030364" target="_blank" >https://doi.org/10.3390/ph18030364</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/ph18030364" target="_blank" >10.3390/ph18030364</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Beyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways
Popis výsledku v původním jazyce
The rising burden of fungal infections presents a significant challenge to global healthcare, particularly with increasing antifungal resistance limiting treatment efficacy. Early detection and timely intervention remain critical, yet fungal pathogens employ diverse mechanisms to evade host immunity and develop resistance, undermining existing therapeutic options. Limited antifungal options and rising resistance necessitate novel treatment strategies. This review provides a comprehensive overview of conventional antifungal agents, their mechanisms of action, and emerging resistance pathways. Furthermore, it highlights recently approved and investigational antifungal compounds while evaluating innovative approaches such as nanotechnology, drug repurposing, and immunotherapy. Addressing antifungal resistance requires a multifaceted strategy that integrates novel therapeutics, enhanced diagnostic tools, and future research efforts to develop sustainable and effective treatment solutions.
Název v anglickém jazyce
Beyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways
Popis výsledku anglicky
The rising burden of fungal infections presents a significant challenge to global healthcare, particularly with increasing antifungal resistance limiting treatment efficacy. Early detection and timely intervention remain critical, yet fungal pathogens employ diverse mechanisms to evade host immunity and develop resistance, undermining existing therapeutic options. Limited antifungal options and rising resistance necessitate novel treatment strategies. This review provides a comprehensive overview of conventional antifungal agents, their mechanisms of action, and emerging resistance pathways. Furthermore, it highlights recently approved and investigational antifungal compounds while evaluating innovative approaches such as nanotechnology, drug repurposing, and immunotherapy. Addressing antifungal resistance requires a multifaceted strategy that integrates novel therapeutics, enhanced diagnostic tools, and future research efforts to develop sustainable and effective treatment solutions.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30104 - Pharmacology and pharmacy
Návaznosti výsledku
Projekt
—
Návaznosti
S - Specificky vyzkum na vysokych skolach
Ostatní
Rok uplatnění
2025
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Pharmaceuticals
ISSN
1424-8247
e-ISSN
1424-8247
Svazek periodika
18
Číslo periodika v rámci svazku
3
Stát vydavatele periodika
CH - Švýcarská konfederace
Počet stran výsledku
33
Strana od-do
364
Kód UT WoS článku
001452121700001
EID výsledku v databázi Scopus
2-s2.0-105000957086